Statins for the primary prevention of cardiovascular disease

Статины для первичной профилактики сердечно-сосудистых заболеваний
George Davey Smith, Shah B J Ebrahim, Mark D. Huffman, Theresa HM Moore, Fiona C. Taylor, Kirsten J. Ward, Ana Filipa Macedo, Margaret Burke, Hawkins C. Gay
2013-01-29

LDL cholesterolcardiovascular diseaseprimary preventionrandomised controlled trialsstatins
BACKGROUND: Reducing high blood cholesterol, a risk factor for cardiovascular disease (CVD) events in people with and without a past history of CVD is an important goal of pharmacotherapy. Statins are the first-choice agents. Previous reviews of the effects of statins have highlighted their benefits in people with CVD. The case for primary prevention was uncertain when the last version of this review was published (2011) and in light of new data an update of this review is required. OBJECTIVES: To assess the effects, both harms and benefits, of statins in people with no history of CVD. SEARCH METHODS: To avoid duplication of effort, we checked reference lists of previous systematic reviews. The searches conducted in 2007 were updated in January 2012. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2022, Issue 4), MEDLINE OVID (1950 to December Week 4 2011) and EMBASE OVID (1980 to 2012 Week 1).There were no language restrictions. SELECTION CRITERIA: We included randomised controlled trials of statins versus placebo or usual care control with minimum treatment duration of one year and follow-up of six months, in adults with no restrictions on total, low density lipoprotein (LDL) or high density lipoprotein (HDL) cholesterol levels, and where 10% or less had a history of CVD. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion and extracted data. Outcomes included all-cause mortality, fatal and non-fatal CHD, CVD and stroke events, combined endpoints (fatal and non-fatal CHD, CVD and stroke events), revascularisation, change in total and LDL cholesterol concentrations, adverse events, quality of life and costs. Odds ratios (OR) and risk ratios (RR) were calculated for dichotomous data, and for continuous data, pooled mean differences (MD) (with 95% confidence intervals (CI)) were calculated. We contacted trial authors to obtain missing data. MAIN RESULTS: The latest search found four new trials and updated follow-up data on three trials included in the original review. Eighteen randomised control trials (19 trial arms; 56,934 participants) were included. Fourteen trials recruited patients with specific conditions (raised lipids, diabetes, hypertension, microalbuminuria). All-cause mortality was reduced by statins (OR 0.86, 95% CI 0.79 to 0.94); as was combined fatal and non-fatal CVD RR 0.75 (95% CI 0.70 to 0.81), combined fatal and non-fatal CHD events RR 0.73 (95% CI 0.67 to 0.80) and combined fatal and non-fatal stroke (RR 0.78, 95% CI 0.68 to 0.89). Reduction of revascularisation rates (RR 0.62, 95% CI 0.54 to 0.72) was also seen. Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects. There was no evidence of any serious harm caused by statin prescription. Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life. Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta-analysis indicate that these benefits are similar in people at lower (< 1% per year) risk of a major cardiovascular event. AUTHORS' CONCLUSIONS: Reductions in all-cause mortality, major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins.
1
Eligible participants had no restrictions on cholesterol levels, and no more than 10% had a previous history of cardiovascular disease.
2
It includes randomized controlled trials comparing statins with placebo or usual care, requiring at least one year of treatment and six months of follow-up.
3
Outcomes assessed included mortality, coronary heart disease, cardiovascular and stroke events, revascularization, cholesterol changes, adverse events, quality of life, and costs.
4
The abstract indicates that the review was updated because evidence for primary prevention remained uncertain in the 2011 version, but it does not provide the updated results.
5
The review evaluates benefits and harms of statins for primary prevention in adults without established cardiovascular disease.

Statin therapy in adults with no history of cardiovascular disease

The benefits and harms of statins for primary prevention of cardiovascular disease

Publication Details
Publication Date
2013-01-29
Journal
Publisher
ISSN
Cited by
1941
Access Type
Author Information
Authors
George Davey Smith
Shah B J Ebrahim
Mark D. Huffman
Theresa HM Moore
Fiona C. Taylor
Kirsten J. Ward
Ana Filipa Macedo
Margaret Burke
Hawkins C. Gay
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%